- Home
- CRVS vs NOA Comparison
CRVS vs NOA Comparison
Compare CRVS & NOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NOA
- Stock Information
- Founded
- CRVS 2014
- NOA 1953
- Country
- CRVS United States
- NOA Canada
- Employees
- CRVS N/A
- NOA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NOA Meat/Poultry/Fish
- Sector
- CRVS Health Care
- NOA Consumer Staples
- Exchange
- CRVS Nasdaq
- NOA Nasdaq
- Market Cap
- CRVS 516.0M
- NOA 556.4M
- IPO Year
- CRVS 2016
- NOA 2006
- Fundamental
- Price
- CRVS $4.99
- NOA $20.28
- Analyst Decision
- CRVS Buy
- NOA
- Analyst Count
- CRVS 4
- NOA 0
- Target Price
- CRVS $12.83
- NOA N/A
- AVG Volume (30 Days)
- CRVS 1.6M
- NOA 56.1K
- Earning Date
- CRVS 11-12-2024
- NOA 10-30-2024
- Dividend Yield
- CRVS N/A
- NOA 1.69%
- EPS Growth
- CRVS N/A
- NOA N/A
- EPS
- CRVS N/A
- NOA 1.41
- Revenue
- CRVS N/A
- NOA $874,213,701.00
- Revenue This Year
- CRVS N/A
- NOA $27.87
- Revenue Next Year
- CRVS N/A
- NOA $8.82
- P/E Ratio
- CRVS N/A
- NOA $12.91
- Revenue Growth
- CRVS N/A
- NOA 35.78
- 52 Week Low
- CRVS $1.30
- NOA $16.46
- 52 Week High
- CRVS $10.00
- NOA $25.92
- Technical
- Relative Strength Index (RSI)
- CRVS 28.00
- NOA 49.78
- Support Level
- CRVS $3.77
- NOA $20.29
- Resistance Level
- CRVS $7.44
- NOA $21.44
- Average True Range (ATR)
- CRVS 0.60
- NOA 0.52
- MACD
- CRVS -0.41
- NOA -0.10
- Stochastic Oscillator
- CRVS 25.85
- NOA 23.24
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NOA North American Construction Group Ltd. (no par)
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment - Canada, Heavy Equipment - Australia, and Other. Heavy Equipment - Canada and Heavy Equipment - Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes our mine management contract work in the United States, its external maintenance and rebuild programs.